Clinical Trial Update: RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on a RIC regimen for low- and intermediate-risk myelodysplastic syndromes undergoing haploidentical hematopoietic stem cell transp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Snippet

Sponsor: Peking University People's Hospital | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: UNKNOWN